Nothing Special   »   [go: up one dir, main page]

CY1122113T1 - Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου - Google Patents

Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου

Info

Publication number
CY1122113T1
CY1122113T1 CY20191100919T CY191100919T CY1122113T1 CY 1122113 T1 CY1122113 T1 CY 1122113T1 CY 20191100919 T CY20191100919 T CY 20191100919T CY 191100919 T CY191100919 T CY 191100919T CY 1122113 T1 CY1122113 T1 CY 1122113T1
Authority
CY
Cyprus
Prior art keywords
pyloros
helicobacterium
treatment
pharmaceutical compositions
disorders associated
Prior art date
Application number
CY20191100919T
Other languages
English (en)
Inventor
Gilead RADAY
Guy GOLDBERG
Patrick Gosselin
Reza Fathi
Original Assignee
Redhill Biopharma Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51297592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122113(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Redhill Biopharma Ltd. filed Critical Redhill Biopharma Ltd.
Publication of CY1122113T1 publication Critical patent/CY1122113T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Στο παρόν προβλέπονται μια ενιαία από του στόματος στερεά δοσολογική μορφή που περιλαμβάνει μια πρώτη δοσολογική σύνθεση άμεσης αποδέσμευσης με τουλάχιστον δύο αντιβιοτικούς παράγοντες και δεύτερη δοσολογική σύνθεση καθυστερημένης αποδέσμευσης με έναν αναστολέα αντλίας πρωτονίων. Η ενιαία από του στόματος στερεά δοσολογική μορφή σύμφωνα με ορισμένες εκδοχές της εφεύρεσης μπορεί να χρησιμοποιηθεί για τη θεραπεία των διαταραχών που συνδέονται με τη λοίμωξη από Η. pylori ή την πρόληψη της επανεμφάνισης διαταραχών που συνδέονται με τη λοίμωξη από Η. pylori.
CY20191100919T 2013-02-13 2019-09-02 Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου CY1122113T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361764401P 2013-02-13 2013-02-13
US201361764385P 2013-02-13 2013-02-13
PCT/US2014/016071 WO2014127025A1 (en) 2013-02-13 2014-02-12 Pharmaceutical compositions for the treatment of helicobacter pylori

Publications (1)

Publication Number Publication Date
CY1122113T1 true CY1122113T1 (el) 2020-11-25

Family

ID=51297592

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100919T CY1122113T1 (el) 2013-02-13 2019-09-02 Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου

Country Status (26)

Country Link
US (8) US9050263B2 (el)
EP (1) EP2956149B1 (el)
JP (1) JP6494529B2 (el)
KR (1) KR102062357B1 (el)
CN (2) CN105163743A (el)
AU (1) AU2014216373B2 (el)
BR (1) BR112015019264B1 (el)
CA (1) CA2900763C (el)
CL (1) CL2015002253A1 (el)
CY (1) CY1122113T1 (el)
DK (1) DK2956149T3 (el)
ES (1) ES2744406T3 (el)
HK (1) HK1217645A1 (el)
HR (1) HRP20191559T1 (el)
HU (1) HUE052411T2 (el)
IL (1) IL240387B (el)
MX (1) MX368536B (el)
NZ (1) NZ711754A (el)
PH (1) PH12015501783B1 (el)
PL (1) PL2956149T3 (el)
PT (1) PT2956149T (el)
RU (1) RU2671400C2 (el)
SG (1) SG11201506318QA (el)
SI (1) SI2956149T1 (el)
UA (1) UA120249C2 (el)
WO (1) WO2014127025A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120249C2 (uk) 2013-02-13 2019-11-11 Редхілл Байофарма Лтд. Фармацевтичні композиції для лікування від helicobacter pylori
KR101884230B1 (ko) * 2016-02-29 2018-08-01 주식회사 유영제약 에소메프라졸을 포함하는 제제
US11110209B2 (en) * 2017-01-18 2021-09-07 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Intraluminal therapy system for gastrointestinal infections
AU2018348777B2 (en) * 2017-10-15 2024-09-12 Centre For Digestive Diseases Compositions and methods for treating, ameliorating and preventing H. pylori infections
CN108497546B (zh) * 2018-03-22 2021-03-19 宝可科技（上海）有限公司 一种烟用添加剂及其制备方法和用途
CN110354125A (zh) * 2019-08-12 2019-10-22 珠海赛隆药业股份有限公司 一种治疗幽门螺杆菌感染的组合物及其制剂和用途
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index
KR20230150745A (ko) * 2022-04-22 2023-10-31 한국생명공학연구원 헬리코박터 파일로리에 의한 위 점막 손상 관련 질환의 예방 또는 치료용 약학적 조성물
CN117398360B (zh) * 2023-12-14 2024-03-15 山东齐都药业有限公司 治疗幽门螺杆菌的复方制剂胶囊及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980637A (en) * 1975-03-17 1976-09-14 Bristol-Myers Company Production of amoxicillin
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
EP0941101A1 (en) 1996-11-22 1999-09-15 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
SE9700885D0 (sv) 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
AUPP325398A0 (en) * 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
US5927500A (en) * 1998-06-09 1999-07-27 Milliken & Company Pharmaceutical containment package
JP2000128779A (ja) * 1998-10-20 2000-05-09 Mitsui Chemicals Inc 薬物放出制御型製剤
US20040213847A1 (en) * 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
EP1803450A1 (en) * 2006-01-03 2007-07-04 Ferrer Internacional, S.A. Pharmaceutical compositions for the eradication of helicobacter pylori
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
JP5260905B2 (ja) 2007-07-12 2013-08-14 株式会社ジャパンディスプレイ 有機ｅｌ表示装置
EP2169399A4 (en) 2007-07-20 2011-05-18 Kowa Co REAGENT FOR MEASURING A LEAD CELL CENTRATION AND METHOD FOR MEASURING A LEAD CONCENTRATION
WO2009017716A2 (en) 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
CN101584681A (zh) * 2008-05-23 2009-11-25 黑龙江福和华星制药集团股份有限公司 一种用于治疗幽门螺旋杆菌感染的片剂胶囊
CN101607086B (zh) * 2009-07-21 2011-11-02 山西安特生物制药股份有限公司 一种复方铋剂组合物及其制备方法
CN102091084B (zh) * 2010-12-09 2012-05-09 王勇 一种复方胶囊及其制备方法
UA120249C2 (uk) * 2013-02-13 2019-11-11 Редхілл Байофарма Лтд. Фармацевтичні композиції для лікування від helicobacter pylori

Also Published As

Publication number Publication date
RU2015138708A (ru) 2017-03-17
PT2956149T (pt) 2019-09-20
US11135172B2 (en) 2021-10-05
HK1217645A1 (zh) 2017-01-20
CA2900763A1 (en) 2014-08-21
US20240325313A1 (en) 2024-10-03
AU2014216373A1 (en) 2015-08-27
US20220062188A1 (en) 2022-03-03
SG11201506318QA (en) 2015-09-29
BR112015019264B1 (pt) 2021-08-24
US9603806B2 (en) 2017-03-28
PH12015501783A1 (en) 2015-12-07
HRP20191559T1 (hr) 2019-11-29
US10898439B2 (en) 2021-01-26
ES2744406T3 (es) 2020-02-25
CA2900763C (en) 2021-04-06
BR112015019264A2 (pt) 2017-07-18
SI2956149T1 (sl) 2019-11-29
US20150044283A1 (en) 2015-02-12
EP2956149B1 (en) 2019-06-19
US20140227353A1 (en) 2014-08-14
AU2014216373B2 (en) 2017-12-21
CN105163743A (zh) 2015-12-16
JP2016508516A (ja) 2016-03-22
US20190336451A1 (en) 2019-11-07
CN109893516A (zh) 2019-06-18
US11931463B2 (en) 2024-03-19
PL2956149T3 (pl) 2020-03-31
PH12015501783B1 (en) 2020-02-14
EP2956149A1 (en) 2015-12-23
US9050263B2 (en) 2015-06-09
RU2671400C2 (ru) 2018-10-31
UA120249C2 (uk) 2019-11-11
US20190175512A1 (en) 2019-06-13
DK2956149T3 (da) 2019-09-09
KR20150118176A (ko) 2015-10-21
US10238606B2 (en) 2019-03-26
HUE052411T2 (hu) 2021-04-28
BR112015019264A8 (pt) 2019-11-12
JP6494529B2 (ja) 2019-04-03
WO2014127025A1 (en) 2014-08-21
US20160235681A1 (en) 2016-08-18
CL2015002253A1 (es) 2016-07-29
MX2015010490A (es) 2015-10-30
MX368536B (es) 2019-10-07
EP2956149A4 (en) 2016-10-12
IL240387B (en) 2020-02-27
US20170189341A1 (en) 2017-07-06
IL240387A0 (en) 2015-09-24
NZ711754A (en) 2020-05-29
KR102062357B1 (ko) 2020-01-03
US9498445B2 (en) 2016-11-22

Similar Documents

Publication Publication Date Title
CY1122113T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου
CY1124007T1 (el) Στοματικες δοσολογικες μορφες παρατεταμενης απελευθερωσης τοφασιτινιμπης
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
ECSP15037311A (es) Formulación combinada de dos compuestos antivirales
CL2016000783A1 (es) “compuestos derivados de isoquinolinona y quinazolinona, inhibidores pi3k; composición farmacéutica que los comprende; útiles en el tratamiento del cáncer, enfermedades inflamatorias y autoinmune”. pct
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
EA202092456A2 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
PH12016500024A1 (en) Bromodomain inhibitor
EA201591531A1 (ru) Ингибиторы аргининметилтрансферазы и их применения
CR20150571A (es) Compuestos y composiciones terapéuticos
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
NI201500115A (es) Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
CY1122387T1 (el) Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
CY1123695T1 (el) Φαρμακευτικη συνθεση με αντιφλεγμονωδεις παραγοντες και διαδικασια παρασκευης
CY1123933T1 (el) Σκευασματα παρατεταμενης αποδεσμευσης λοραζεπαμης
GEP201706743B (en) Oral formulation for the treatment of cardiovascular diseases
TR201310724A2 (tr) Linagliptinin farmasotik formulasyonları.
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação